Abstract 2142
Background
Renal cell carcinoma (RCC) is considered an immunogenic cancer with a high frequency of indel mutations, immuno-oncological (IO) sensitivity, and infiltration of T cells. Because natural killer (NK) cells are a lesser known population compared to their T cell counterparts, we aimed to investigate the intratumoral phenotype of the cells to assess the overall immune landscape of RCC.
Methods
The tumor, matching peripheral blood (PB) and healthy kidney tissue samples were obtained from 40 RCC patients that underwent radical nephrectomy and were phenotyped using multi-parameter flow cytometry and a comprehensive immunostaining panel containing 56 fundamental markers to cancer immunology.
Results
Using hierarchical clustering and correlation analysis, we discovered that our cohort clustered into two distinct subgroups defined by the abundance of NK cells from the intratumoral lymphocyte population, defined as NKhigh (n = 17; mean 24.3%) and NKlow (n = 18; mean 7.5%). Consequently, an increased abundance of NK cells correlated with a lower expression of PD-1, particularly in the CD8+ T cells (r=-0.5722, p = 0.0003), but not with LAG-3. Contrastingly, clinical parameters such as tumor grade, gender and age did not differ between the two NK subgroups. However, patients with high NK cell abundance significantly had more often necrosis present in the tumors (p = 0.04). We also independently phenotyped two regions of the same tumor sample (n = 10) to compare the periphery and core lymphocytes. Surprisingly, both spatially different regions displayed similar quantities of immune cell populations and immunophenotypic markers. Overall, the tumor immune landscape in RCC resulted in a proportion of tumors carrying a higher abundance of NK cells than their T cell-rich corresponding PB and healthy tissue samples, which supports our findings that a proportion of tumors accumulate NK cells.
Conclusions
Our study has led to the discovery of two distinct RCC tumoral NK cell subgroups, NKhigh and NKlow. Next, we aim to further explore the transcriptional differences of the two subgroups with ongoing bulk RNA sequencing (RNAseq). Furthermore, prospective single-cell RNA sequencing (sc-RNAseq) will be carried out to investigate the immunological heterogeneities in higher resolution.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
University of Helsinki, Hematology Research Unit Helsinki.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4290 - Characterization of the mechanism of action and efficacy of MEN1611 (PA799), a novel PI3K inhibitor, in breast cancer preclinical models.
Presenter: Alessio Fiascarelli
Session: Poster Display session 3
Resources:
Abstract
2167 - Neat-1: culprit lnRNA tying PIG-C, MSLN, CD80 in TNBC
Presenter: Nada Hussein
Session: Poster Display session 3
Resources:
Abstract
1829 - A novel RAF/MEK inhibitor CH5126766 in phase 1 clinical trial has an effectiveness in the combination with eribulin for the treatment of triple negative breast cancer
Presenter: Hisako Ono
Session: Poster Display session 3
Resources:
Abstract
4357 - Identification of a stemness-related gene panel associated with BET inhibition in triple negative breast cancer
Presenter: Eva Galan-Moya
Session: Poster Display session 3
Resources:
Abstract
5163 - Preclinical Evaluation targeting both IGF1R and IR in Triple Negative Breast Cancer
Presenter: Alex Eustace
Session: Poster Display session 3
Resources:
Abstract
832 - Monospecific antibody targeting of CDH11 inhibits epithelial-to-mesenchymal transition and represses cancer stem cell-like phenotype by up-regulating miR-335 in metastatic breast cancer, in vitro and in vivo.
Presenter: Jia-Hong Chen
Session: Poster Display session 3
Resources:
Abstract
3781 - Pharmacological screening with Chk1 inhibitors identify synergistic agents to overcome resistance to platinums in basal breast and ovarian cancer
Presenter: Ana Lucia Sanabria
Session: Poster Display session 3
Resources:
Abstract
3275 - Comparison of 11 circulating miRNAs and CA125 kinetics in ovarian cancer during first line treatment: data from the randomized CHIVA trial (a GINECO-GCIG study)
Presenter: Patrick Robelin
Session: Poster Display session 3
Resources:
Abstract
3391 - Inhibiting Ehmt2 and Ezh2 histone methyltransferases alters the immune microenvironment in a Trp53-/- murine ovarian cancer model
Presenter: Pavlina Spiliopoulou
Session: Poster Display session 3
Resources:
Abstract
3839 - Fenofibrate impairs pro-tumorigenic potential of cancer stem cell-like cells within drug-resistant prostate cancer cell populations.
Presenter: Tomasz Wróbel
Session: Poster Display session 3
Resources:
Abstract